Skip to main content
. Author manuscript; available in PMC: 2024 Apr 2.
Published in final edited form as: Cancer Res. 2020 Nov 17;81(3):671–684. doi: 10.1158/0008-5472.CAN-20-1414

Figure 2: Suppressive function segregates with the FRβ+ populations.

Figure 2:

(A and B) Analysis of suppression within FRβ positive and negative M-MDSCs and TAMs. M-MDSCs (A) and TAMs (B) were divided into FRβ+/− subsets from IP RM-1 tumors and tested in an 18 hr. suppression assay as described in panel A under either normoxic or hypoxic (1% O2) conditions. (n=5 mice per group pooled and data is representative of 4 independent experiments) (C and D) Determination of the hypoxic status of tumor-derived and spleen MDSCs and TAMs in tumor bearing mice. IP RM-1 tumor-bearing mice were treated with pimonidizole (60 mg/Kg of body mass by IP injection) 1.5 hrs. prior to harvest. Tumors were isolated and labeled with antibodies against MDSCs and TAM markers along with an antibody against pimonidizole. Under hypoxic conditions pimonidizole forms adducts in protein that can be detected via antibody. Red histogram is FRβ+ population, blue histogram is FRβ− population, and green histogram is spleen isolated population. (data representative of 5 mice)